Compare FMNB & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FMNB | DRUG |
|---|---|---|
| Founded | 1887 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Pharmaceuticals and Biotechnology |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 884.6M | 778.4M |
| IPO Year | 2010 | 2020 |
| Metric | FMNB | DRUG |
|---|---|---|
| Price | $15.34 | $49.90 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | $17.00 | ★ $152.40 |
| AVG Volume (30 Days) | ★ 291.4K | 130.4K |
| Earning Date | 11-03-2026 | 08-17-2026 |
| Dividend Yield | ★ 4.65% | N/A |
| EPS Growth | ★ 18.85 | N/A |
| EPS | ★ 0.76 | N/A |
| Revenue | ★ $279,922,000.00 | N/A |
| Revenue This Year | $39.49 | N/A |
| Revenue Next Year | $7.45 | N/A |
| P/E Ratio | $20.39 | ★ N/A |
| Revenue Growth | ★ 3.89 | N/A |
| 52 Week Low | $12.23 | $47.23 |
| 52 Week High | $16.46 | $123.75 |
| Indicator | FMNB | DRUG |
|---|---|---|
| Relative Strength Index (RSI) | 50.59 | 40.14 |
| Support Level | $14.80 | $47.23 |
| Resistance Level | $15.43 | $55.78 |
| Average True Range (ATR) | 0.25 | 3.86 |
| MACD | 0.04 | 0.86 |
| Stochastic Oscillator | 64.29 | 25.48 |
Farmers National Banc Corp is a financial holding company based in the U.S. Along with its subsidiaries, it operates in the domestic banking, trust, retirement consulting, insurance, and financial management industries. The group offers a full range of commercial and retail banking services, including checking accounts, savings accounts, time deposit accounts, commercial, mortgage, and installment loans, safe deposit boxes, ATMs, internet banking, and other banking services. Additionally, it offers personal and corporate trust services in the areas of estate settlement, trust administration, employee benefit plans, and retirement services; insurance products, and other financial products and services. The group's reportable segments are Bank, which generates the maximum revenue, and Trust.
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.